The research and development at Symmetric Computing has resulted in both a US patent for a new computer architecture and an innovation award from NIH. The company’s Distributed Symmetric Multiprocessing (DSMP) computer architecture allows a multi-node compute cluster to operate as a single global shared memory, multi-threaded supercomputer. This simplifies programming of very complicated simulations. Symmetric’s Virtual Drug Discovery Platform provides new approaches to drug discovery by successfully identifying precursor compounds. They have identified compounds from our database of one billion small molecules which may lead to the development of drugs for treating Opioid Use Disorder, Type 1 Diabetes, and coronavirus infections such as COVID19.
MassBio Member Spotlight: Symmetric Computing, Inc.
Location: Venture Development Center (UMass),100 Morrissey Blvd., Boston, Massachusetts 02125
Therapeutic area(s) or business type (for non-biotechs): Symmetric Computing employs high performance computing to support drug discovery and large database development. The company builds and installs tightly coupled computing clusters characterized by large memory and hybrid CPU/GPU computing. They also develop highly optimized software systems that take advantage of our hardware. A key example is the Virtual Drug Discovery Platform (VDDP), which incorporates molecular dynamics/docking, advanced databases and artificial intelligence to find small molecules and other entities that bind to targeted sites on a protein. Symmetric Computing partners with biotech researchers and pharmaceutical companies to greatly accelerate drug discovery.
Leadership: Richard Anderson | President, CTO, and Co-founder
Website: symmetriccomputing.com